[EN] PYRROLOBENZODIAZEPINE DERIVATIVES AS INHIBITORS OF NF-KAPPA B FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE PYRROLOBENZODIAZÉPINE UTILES EN TANT QU'INHIBITEURS DE NF-KAPPA B POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
申请人:KING S COLLEGE LONDON
公开号:WO2020152462A1
公开(公告)日:2020-07-30
The invention relates to a compound of formula (I) or salts, solvates, stereoisomers, tautomers or combinations thereof, wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; and R1 and R2 are either (i) R1 and R2 together form a double bond; (ii) R1 is H and R2 is OH; or (iii) R1 is H and R2 is OC1-6 alkyl; Y is N-RB, S or O; Y1 is N or C-R8; q is o or 1; Het is where the carbonyl of the Het group is attached to the Y- & Y1-containing heterocyclic ring; Y2 is N-RB, S or O; Y3 is N or C-R10; Y4 is N-RB, S or O; Y5 is N or C-R10; Rx is H, RB, (CH2)m-ORB, halo, (CH2)m-NHRB and CO2RB; and each RB is independently selected from H, C1-6 alkyl and C1-6 haloalkyl. The invention also describes pharmaceutical compositions, and kits comprising compounds of formula (I) and their use for treating proliferative diseases such as multiple myeloma or chronic lymphocytic leukaemia and as NF-κΒ inhibitors.
该发明涉及公式(I)的化合物或其盐、溶剂合物、立体异构体、互变异构体或它们的组合,其中虚线表示C1和C2或C2和C3之间的双键的可选存在;R1和R2要么(i)R1和R2一起形成双键;(ii)R1为H且R2为OH;或(iii)R1为H且R2为OC1-6烷基;Y为N-RB、S或O;Y1为N或C-R8;q为0或1;Het是Het基团的羰基连接到含有Y和Y1的杂环环上;Y2为N-RB、S或O;Y3为N或C-R10;Y4为N-RB、S或O;Y5为N或C-R10;Rx为H、RB、(CH2)m-ORB、卤素、(CH2)m-NHRB和CO2RB;每个RB独立选择自H、C1-6烷基和C1-6卤代烷基。该发明还描述了制药组合物和包含公式(I)化合物的试剂盒,以及它们在治疗增殖性疾病如多发性骨髓瘤或慢性淋巴细胞白血病以及作为NF-κΒ抑制剂的用途。